Canada Pension Plan Investment Board decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 413,492 shares of the life sciences company's stock after selling 41,150 shares during the period. Canada Pension Plan Investment Board owned approximately 0.26% of Illumina worth $55,255,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. WCM Investment Management LLC increased its holdings in Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Illumina by 0.8% during the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after buying an additional 27,618 shares in the last quarter. Norges Bank acquired a new position in Illumina in the 4th quarter valued at $228,714,000. Bessemer Group Inc. lifted its stake in shares of Illumina by 32,837.5% during the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock worth $180,152,000 after purchasing an additional 1,344,038 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of Illumina by 245.7% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company's stock worth $158,011,000 after purchasing an additional 840,423 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Stock Performance
Shares of ILMN traded up $1.57 during mid-day trading on Thursday, hitting $77.82. The stock had a trading volume of 433,119 shares, compared to its average volume of 2,512,565. The company has a market cap of $12.32 billion, a PE ratio of -10.13, a PEG ratio of 1.60 and a beta of 1.38. The company's fifty day simple moving average is $82.95 and its two-hundred day simple moving average is $119.06. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on ILMN shares. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $156.00 target price on shares of Illumina in a research report on Tuesday, March 11th. Morgan Stanley dropped their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and decreased their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Royal Bank of Canada dropped their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $138.70.
Get Our Latest Stock Analysis on ILMN
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
